Fig. 1From: Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologicsDrug survival rate of another JAK inhibitor after failure to a JAKi and subsequent bDMARD(s). JAK, Janus kinase; bDMARD, biologic disease-modifying anti-rheumatic drugBack to article page